MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-DL-06-0006756
Market Cap
₹34.89 Cr
MEDIORG-SM · NSE
Share Price
₹24.60
+4.90% today
Revenue
₹22.63 Cr
FY 2025-26 · -40.7% YoY
EBITDA
−₹3.75 Cr
Margin -16.6%
Net Profit
−₹4.02 Cr
FY 2025-26 · -198.8% YoY
Authorised capital
₹20 Cr
Registered with MCA
Paid-up capital
₹14.88 Cr
Issued & subscribed
Open charges
₹9.35 Cr
Satisfied ₹17.34 Cr
About Medicamen Organics Limited.
Data last updated:
Medicamen Organics Limited. is a public limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 15 March 1995 and has been in existence for over 31 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN L74899DL1995PLC066416. Its GSTIN is 07AABCM4302P1ZF (Delhi). The company holds 5 GST registrations, of which 4 are active. It is a listed company as per MCA records. Its shares are listed on NSE: MEDIORG.
The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹14.88 Cr. It is led by directors including Bal Kishan Gupta (Managing Director) and Ashutosh Gupta (Whole-Time Director).
Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 10 Community Centre No 2 Ashok Vihar Phase II, New Delhi, Delhi, India – 110052.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹22.63 Cr, a decline of 40.7% compared to the previous year. For the same year it recorded a net loss of ₹4.02 Cr (net margin -17.8%) and EBITDA of -₹3.75 Cr (EBITDA margin -16.6%). The net worth stands at ₹28.73 Cr (down 4.6% YoY). Total assets are valued at ₹43.13 Cr (up 0.1% YoY).
The company has about 33 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Medicamen Organics. As per MCA filings, the company has open charges of ₹9.35 Cr and satisfied charges of ₹17.34 Cr on record. Court records list 26 cases involving the company, including 9 filed by the company and 17 filed against it; 7 cases are pending. The company has 1 deal on record (1 ipo); the latest was in June 2024. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 4 smaller; the largest is Sigma Laboratories Private Limited with revenue of ₹38.91 Cr. The company has 1 MSME Form 1 return on record for the period ending Sep 2023, listing 241 overdue payments to 21 micro and small suppliers.
Medicamen Organics Limited. is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-DL-06-0006756). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medicamenorganics.com.
Company details
CIN L74899DL1995PLC066416
Registration Number 066416
Incorporation Date 15 March 1995
ROC Delhi
Listing Status Listed (NSE: MEDIORG)
Company Status Active
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-DL-06-0006756
CIN history
Medicamen Organics Limited has one previous CIN (Corporate Identification Number): U74899DL1995PLC066416. The current CIN is L74899DL1995PLC066416, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L74899DL1995PLC066416 | Current |
| U74899DL1995PLC066416 | Previous |
Key People
Bal Kishan Gupta Managing Director Ashutosh Gupta Whole-Time Director Rakesh Kumar Director Recognitions & Rankings of Medicamen Organics Limited
Contact details
Medicamen Organics Limited.'s registered office is in New Delhi, Delhi. Its website is medicamenorganics.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address10 Community Centre No 2 Ashok Vihar Phase II, New Delhi, Delhi, India – 110052
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Medicamen Organics Limited., buy the company report.
Comprehensive company report
Medicamen Organics Limited. - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Medicamen Organics Limited operates one associated brand: Medicamen Organics. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical formulations are manufactured as a CDMO by Medicamen Organics. | medicamenorganics.com |
Business activity
The main business activity of Medicamen Organics Limited is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Medicamen Organics Limited., buy the company report.
Financials of Medicamen Organics Limited.
FY 2025-26 filings availableMedicamen Organics Limited. reported revenue of ₹22.63 Cr (down 40.7% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹22.63 Cr
-40.7% YoY
EBITDA
−₹3.75 Cr
-156.6% YoY
Profit After Tax
−₹4.02 Cr
-198.8% YoY
Net Worth
₹28.73 Cr
-4.6% YoY
Total Assets
₹43.13 Cr
+0.1% YoY
Total Debt
₹14.29 Cr
+15.7% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue | 22.63 | 38.19 | 25.27 |
| Revenue growth | -40.7% | +51.1% | - |
| EBITDA | (3.75) | 6.63 | 5.79 |
| EBITDA margin | -16.6% | +17.4% | +22.9% |
| Profit before tax | (5.28) | 5.45 | 4.44 |
| Net profit | (4.02) | 4.07 | 2.01 |
| Net profit margin | -17.8% | +10.7% | +8.0% |
| EPS (₹) | (3.41) | 3.46 | 3.05 |
| Balance sheet | |||
| Total assets | 43.13 | 43.09 | 28.13 |
| Net worth | 28.73 | 30.13 | 15.26 |
| Total debt | 14.29 | 12.35 | 12.66 |
| Cash & bank | 1.30 | 4.13 | 0.55 |
| Net working capital | 28.35 | 30.47 | 18.19 |
| Cash flow | |||
| Cash from operations | (4.60) | (4.54) | (3.66) |
| Cash from investing | (1.72) | (2.35) | (0.34) |
| Cash from financing | 3.48 | 10.47 | 4.01 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 21.65 | 37.09 | 25.27 | 22.15 | 20.98 | 25.05 | 31.49 |
| Revenue growth | -41.6% | +46.8% | +14.1% | +5.6% | -16.3% | -20.5% | - |
| EBITDA | (2.78) | 5.58 | 5.79 | 1.87 | 1.19 | 1.63 | 1.36 |
| EBITDA margin | -12.8% | +15.0% | +22.9% | +8.4% | +5.7% | +6.5% | +4.3% |
| Profit before tax | (4.31) | 4.40 | 4.44 | 1.37 | 0.25 | 0.48 | 0.22 |
| Net profit | (3.05) | 3.29 | 2.01 | 0.98 | 0.09 | 0.28 | 0.12 |
| Net profit margin | -14.1% | +8.9% | +8.0% | +4.4% | +0.4% | +1.1% | +0.4% |
| EPS (₹) | (2.58) | 2.80 | 3.05 | 1.62 | 0.15 | 0.50 | 0.17 |
| Balance sheet | |||||||
| Total assets | 42.74 | 42.11 | 28.13 | 20.99 | 18.03 | 17.25 | 15.52 |
| Net worth | 28.81 | 29.72 | 15.26 | 8.98 | 7.56 | 7.47 | 7.11 |
| Total debt | 13.69 | 12.13 | 12.66 | 11.79 | 10.24 | 9.59 | 8.27 |
| Cash & bank | 0.60 | 3.27 | 0.55 | 0.53 | 0.44 | 0.88 | 0.81 |
| Net working capital | 27.81 | 29.24 | 18.19 | 10.44 | 7.44 | 6.61 | 4.23 |
| Cash flow | |||||||
| Cash from operations | (4.15) | (4.91) | (3.66) | (0.58) | 0.04 | (1.16) | 1.58 |
| Cash from investing | (1.63) | (2.62) | (0.34) | (0.28) | (0.59) | (0.02) | (0.45) |
| Cash from financing | 3.10 | 10.25 | 4.01 | 0.94 | 0.18 | 1.27 | (0.55) |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 13 Nov 2026
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue | 22.63 | 38.19 | 25.27 |
| Revenue growth | -40.7% | +51.1% | - |
| Other income | 0.08 | 0.10 | 0.02 |
| Total expenses | 26.38 | 31.56 | 19.48 |
| Employee cost | 0.00 | 3.16 | 2.94 |
| EBITDA | (3.75) | 6.63 | 5.79 |
| EBITDA margin | -16.6% | +17.4% | +22.9% |
| Depreciation | 0.90 | 0.74 | 0.72 |
| Interest | 0.71 | 0.54 | 0.65 |
| Profit before tax | (5.28) | 5.45 | 4.44 |
| Tax | (1.26) | 1.38 | 1.81 |
| Net profit | (4.02) | 4.07 | 2.01 |
| Net profit margin | -17.8% | +10.7% | +8.0% |
| EPS (₹) | (3.41) | 3.46 | 3.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 12.17 | 11.70 | 8.60 |
| Reserves & surplus | 16.56 | 17.68 | 6.66 |
| Shareholders' funds (net worth) | 28.73 | 30.13 | 15.26 |
| Minority interest | (0.14) | 0.35 | 0.00 |
| Secured loans | 7.85 | 4.76 | 5.69 |
| Unsecured loans | 6.44 | 7.59 | 6.97 |
| Total debt | 14.29 | 12.35 | 12.66 |
| Total liabilities | 43.13 | 43.09 | 28.13 |
| Assets | |||
| Gross block | 22.15 | 18.37 | 18.00 |
| Net block | 13.37 | 10.13 | 10.35 |
| Capital work in progress | 0.09 | 2.22 | 0.15 |
| Investments | 0.00 | 0.00 | 0.00 |
| Inventories | 10.52 | 7.49 | 6.14 |
| Sundry debtors | 18.62 | 25.85 | 16.70 |
| Cash & bank balances | 1.30 | 4.13 | 0.55 |
| Loans & advances | 6.41 | 7.96 | 3.92 |
| Total current assets | 36.85 | 45.43 | 27.31 |
| Total current liabilities | 8.50 | 14.96 | 9.12 |
| Net working capital | 28.35 | 30.47 | 18.19 |
| Total assets | 43.13 | 43.09 | 28.13 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Opening cash | 4.13 | 0.55 | 0.54 |
| Net cash from operating activities | (4.60) | (4.54) | (3.66) |
| Net cash from investing activities | (1.72) | (2.35) | (0.34) |
| Net cash from financing activities | 3.48 | 10.47 | 4.01 |
| Net change in cash | (2.83) | 3.58 | 0.01 |
| Closing cash | 1.30 | 4.13 | 0.55 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Growth | |||
| Sales growth | -40.7% | +51.1% | - |
| EBITDA growth | -156.6% | +14.5% | - |
| PBT growth | - | +22.8% | +9997.0% |
| Net income growth | -198.8% | +102.5% | - |
| Profitability & leverage | |||
| Net income margin | -17.8% | +10.7% | +10.4% |
| Return on capital employed | - | +16.9% | +14.3% |
| Return on net worth | - | +17.9% | +13.1% |
| Debt / equity | - | 0.55 | 0.83 |
| Long-term debt / equity | - | 0.01 | 0.01 |
| Interest cover | -15.27 | 9.17 | 12.82 |
| Efficiency & per share | |||
| Fixed asset turnover | - | 2.10 | 1.40 |
| Inventory turnover | - | 5.60 | 4.12 |
| Debtors turnover | - | 1.80 | 1.51 |
| EPS (₹) | (3.41) | 3.46 | 3.05 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 25.11 | 17.74 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 21.65 | 37.09 | 25.27 | 22.15 | 20.98 | 25.05 | 31.49 |
| Revenue growth | -41.6% | +46.8% | +14.1% | +5.6% | -16.3% | -20.5% | - |
| Other income | 0.07 | 0.10 | 0.02 | 0.82 | 0.21 | 0.01 | 0.09 |
| Total expenses | 24.43 | 31.51 | 19.48 | 20.28 | 19.79 | 23.42 | 30.13 |
| Employee cost | 0.00 | 3.23 | 2.99 | 2.87 | 2.49 | 2.33 | 2.58 |
| EBITDA | (2.78) | 5.58 | 5.79 | 1.87 | 1.19 | 1.63 | 1.36 |
| EBITDA margin | -12.8% | +15.0% | +22.9% | +8.4% | +5.7% | +6.5% | +4.3% |
| Depreciation | 0.89 | 0.74 | 0.72 | 0.71 | 0.68 | 0.68 | 0.77 |
| Interest | 0.71 | 0.54 | 0.65 | 0.61 | 0.47 | 0.48 | 0.46 |
| Profit before tax | (4.31) | 4.40 | 4.44 | 1.37 | 0.25 | 0.48 | 0.22 |
| Tax | (1.26) | 1.11 | 1.81 | 0.39 | 0.16 | 0.20 | 0.10 |
| Net profit | (3.05) | 3.29 | 2.01 | 0.98 | 0.09 | 0.28 | 0.12 |
| Net profit margin | -14.1% | +8.9% | +8.0% | +4.4% | +0.4% | +1.1% | +0.4% |
| EPS (₹) | (2.58) | 2.80 | 3.05 | 1.62 | 0.15 | 0.50 | 0.17 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 12.17 | 11.70 | 8.60 | 6.00 | 6.00 | 6.00 | 6.00 |
| Reserves & surplus | 16.64 | 17.27 | 6.66 | 2.98 | 1.56 | 1.47 | 1.11 |
| Shareholders' funds (net worth) | 28.81 | 29.72 | 15.26 | 8.98 | 7.56 | 7.47 | 7.11 |
| Secured loans | 7.85 | 4.76 | 5.69 | 5.55 | 5.07 | 4.35 | 3.60 |
| Unsecured loans | 5.84 | 7.37 | 6.97 | 6.24 | 5.17 | 5.24 | 4.67 |
| Total debt | 13.69 | 12.13 | 12.66 | 11.79 | 10.24 | 9.59 | 8.27 |
| Total liabilities | 42.74 | 42.11 | 28.13 | 20.99 | 18.03 | 17.25 | 15.52 |
| Assets | |||||||
| Gross block | 22.15 | 18.37 | 18.00 | 16.74 | 16.46 | 15.84 | 15.81 |
| Net block | 13.28 | 10.13 | 10.35 | 10.86 | 11.30 | 11.36 | 11.27 |
| Capital work in progress | 0.09 | 2.22 | 0.15 | 0.00 | 0.00 | 0.00 | 0.06 |
| Investments | 0.27 | 0.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 10.30 | 7.49 | 6.14 | 6.14 | 4.72 | 2.66 | 4.37 |
| Sundry debtors | 17.97 | 24.75 | 16.70 | 10.77 | 6.25 | 7.53 | 5.52 |
| Cash & bank balances | 0.60 | 3.27 | 0.55 | 0.53 | 0.44 | 0.88 | 0.81 |
| Loans & advances | 6.69 | 7.91 | 3.92 | 3.43 | 4.03 | 3.65 | 3.61 |
| Total current assets | 35.56 | 43.42 | 27.31 | 20.87 | 15.44 | 14.72 | 14.31 |
| Total current liabilities | 7.75 | 14.18 | 9.12 | 10.43 | 8.00 | 8.11 | 10.08 |
| Net working capital | 27.81 | 29.24 | 18.19 | 10.44 | 7.44 | 6.61 | 4.23 |
| Total assets | 42.74 | 42.11 | 28.13 | 20.99 | 18.03 | 17.25 | 15.52 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.27 | 0.55 | 0.54 | 0.37 | 0.74 | 0.65 | 0.23 |
| Net cash from operating activities | (4.15) | (4.91) | (3.66) | (0.58) | 0.04 | (1.16) | 1.58 |
| Net cash from investing activities | (1.63) | (2.62) | (0.34) | (0.28) | (0.59) | (0.02) | (0.45) |
| Net cash from financing activities | 3.10 | 10.25 | 4.01 | 0.94 | 0.18 | 1.27 | (0.55) |
| Net change in cash | (2.67) | 2.72 | 0.01 | 0.07 | (0.37) | 0.09 | 0.58 |
| Closing cash | 0.60 | 3.27 | 0.55 | 0.53 | 0.44 | 0.88 | 0.81 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -41.6% | +46.8% | +14.1% | +5.6% | -16.3% | -20.5% | - |
| EBITDA growth | -149.8% | -3.6% | +209.6% | +57.1% | -27.0% | +19.9% | - |
| PBT growth | - | -0.9% | +224.1% | +448.0% | -47.9% | +118.2% | +9997.0% |
| Net income growth | -192.7% | +63.7% | +105.1% | +988.9% | -67.9% | +133.3% | - |
| Revenue CAGR (3Y) | -0.8% | +20.9% | +0.3% | -11.1% | - | - | - |
| EBITDA CAGR (3Y) | - | +67.4% | +52.6% | +11.2% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | -14.1% | +8.9% | +10.4% | +4.4% | +0.4% | +1.1% | +0.4% |
| Return on capital employed | - | +14.0% | +16.4% | +10.1% | +4.1% | +5.9% | +4.3% |
| Return on net worth | - | +14.5% | +16.5% | +11.7% | +1.2% | +4.1% | +1.4% |
| Debt / equity | - | 0.55 | 1.01 | 1.33 | 1.32 | 1.23 | 1.16 |
| Long-term debt / equity | - | 0.01 | 0.02 | 0.06 | 0.09 | 0.07 | 0.06 |
| Interest cover | -19.35 | 11.16 | 12.82 | 52.59 | 92.16 | 50.53 | 77.97 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 2.04 | 1.45 | 1.33 | 1.30 | 1.58 | 1.99 |
| Inventory turnover | - | 5.44 | 4.12 | 4.08 | 5.69 | 7.13 | 7.21 |
| Debtors turnover | - | 1.79 | 1.84 | 2.60 | 3.04 | 3.84 | 5.70 |
| EPS (₹) | (2.58) | 2.80 | 3.05 | 1.62 | 0.15 | 0.50 | 0.17 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 24.76 | 17.74 | 14.97 | 12.60 | 12.45 | 11.85 |
To see the full year-wise statements and ratios of Medicamen Organics Limited., buy the company report.
Board of directors of Medicamen Organics Limited.
Medicamen Organics Limited has 7 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ashutosh Gupta Also directs: Redline Health Care Private Limited, Orgomed Healthcare LLP, Orgomed Lifecare LLP and 2 more | Whole-Time Director | 01 Apr 2004 | 22 Years 7 Months | Current |
| Bal Kishan Gupta Also directs: Jasbal Pharma LLP, Redline Health Care Private Limited | Managing Director | 15 Mar 1995 | 31 Years 7 Months | Current |
| Rakesh Kumar | Director | 22 Dec 2023 | 2 Years 10 Months | Current |
| Rajinder Kumar Gupta | Director | 01 Dec 2023 | 2 Years 11 Months | Current |
| Sneh Gaur | Director | 01 Dec 2023 | 2 Years 11 Months | Current |
| Sachin Gupta | Director | 01 Dec 2023 | 2 Years 11 Months | Current |
Showing 6 of 7 current directors. View all directors
Peer comparison
Medicamen Organics Limited. is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sigma Laboratories Private Limited | ₹38.91 Cr (FY 2025) | -26.0% | Mumbai, Maharashtra, India | |||
| Revinto Life Science Private Limited | ₹38.71 Cr (FY 2024) | 44.0% | Karwar, Karnataka, India | |||
| Ultra Laboratories Private Limited | ₹38.64 Cr (FY 2024) | 36.0% | Bangalore, Karnataka, India | |||
| Diamond Drugs Private Limited | ₹38.26 Cr (FY 2024) | 2.0% | Kolkata, West Bengal, India | |||
| Klar Sehen Pvt Ltd | ₹38.16 Cr (FY 2016) | 18.0% | Bidar, Karnataka, India | |||
| Tulip Lab Private Limited | ₹38.12 Cr (FY 2023) | -78.0% | Mumbai, Maharashtra, India | |||
| Biomax Biotechnics Private Limited | ₹38.1 Cr (FY 2025) | 9.0% | Chandigarh, India | |||
| Medicamen Organics Limited.this company | ₹22.63 Cr (FY 2026) | -₹4.02 Cr | -17.8% | -40.7% | 33 | New Delhi, Delhi, India |
To see the full peer comparison of Medicamen Organics Limited., buy the company report.
Auditor
Medicamen Organics Limited. is audited by Ashok Sharma & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Ashok Sharma & Associates | FY 2023 | 004161N |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 59.70%, foreign institutional investors hold 0.10%, domestic institutional investors hold 1.60% and retail and other public shareholders hold 38.60%.
Sep 2026
QUARTER
59.70% Promoters
1.60% DII (Domestic Institutional)
0.10% FII (Foreign Institutional)
38.60% Retail & Others
Promoter holding - history
Now 59.70% · Sep 2026High 59.70% · Dec 2025Low 59.70% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 59.70% | 59.70% | 59.70% | 59.70% |
| Public | 40.30% | 40.30% | 40.30% | 40.30% |
Charges & borrowings
Open charges
₹9.35 Cr
Satisfied charges
₹17.34 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 28 Jun 2025 | 101171485 | Others | ₹24 Lakh | Open | |
| 26 Jun 2024 | 100941572 | Hdfc Bank Limited | ₹15.75 Lakh | Open | |
| 15 Mar 2024 | 100888249 | Axis Bank Limited | ₹16.95 Lakh | Open | |
| 07 Jul 2021 | 100479053 | Axis Bank Limited | ₹28.69 Lakh | Open | |
| 27 Nov 2019 | 100307662 | Axis Bank Limited | ₹8.5 Cr | Open |
To see the full charge records of Medicamen Organics Limited., buy the company report.
Total charge records: 9 View all charges
Deals & funding
Medicamen Organics Limited. has 1 deal on record (1 ipo); the latest was in June 2024.
Total deals
1
IPO
1
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2024 | IPO | ₹10.54 Cr | Investors: Rajasthan Global Securities Private Limited , SB Opportunities Fund |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Medicamen Organics Limited. has 26 court cases on record: 9 filed by Medicamen Organics Limited, 17 filed against it. 7 cases are pending and 19 are disposed.
Total cases
26
Filed by the company
9
Filed against the company
17
Pending
7
Disposed
19
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 25 | 16 | 7 |
| High courts | 1 | 1 | 0 |
Cases on record (5 of 26)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, New Delhi, Delhi | Court case (CS (COMM.)) | Filed against the company by Multani Pharmaceuticals Ltd. (Analytical Division) | Pending |
| District court, North West, Delhi | Court case (CS (COMM.)) | Filed by the company against Europa Biocare Private Limited | Pending |
| District court, North West, Delhi | Cheque dishonour complaint | Filed by the company against M/S Wafture Healthcare Private Limited | Pending |
| District court, Sirmaur, Himachal Pradesh | Cheque dishonour complaint | Filed against the company by Symbiosis Pharmaceuticals Pvt. Ltd. | Disposed |
| District court, North West, Delhi | Court case (CS (COMM.)) | Filed by the company against M/S Paseca Healthcare LLP and 3 others | Disposed |
To see the full case history of Medicamen Organics Limited., buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Medicamen Organics Limited. has 1 MSME Form 1 return on record for the period ending Sep 2023, listing 241 overdue payments to 21 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 21)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Shree Krishna Analytical Services Private Limited | |||
| Lotuskind Life Care Private Limited | |||
| Orgachemie Agencies | |||
| Mosiac Colour Impex Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Medicamen Organics Limited., buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Medicamen Organics Limited. has a workforce of 33 employees on its EPFO records as of May 2026, across 3 active EPFO establishments.
Employee count
33
Active EPFO establishments
3
Employee growth
-62.5%
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 33 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Medicamen Organics Limited., buy the company report.
GST
Medicamen Organics Limited has 5 GST registrations: 4 active and 1 cancelled or inactive.
Total GSTINs
5
Active
4
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AABCM4302P1ZF | Delhi | Active | 01 Jul 2017 |
| 05AABCM4302P1ZJ | Uttarakhand | Active | 01 Jul 2017 |
| 05AABCM4302P2ZI | Uttarakhand | Active | 26 Aug 2017 |
| 05AABCM4302P3ZH | Uttarakhand | Active | 03 Apr 2018 |
To see the full GST registrations and return filing status of Medicamen Organics Limited., buy the company report.
Recent activity
Medicamen Organics Limited. has 22 board changes on record since 1995: 15 appointments and 7 cessations. The latest: Pankaj Tiwari was appointed as Director on 09 Apr 2026.
Appointed
Pankaj Tiwari was appointed as Director.
Filing
Medicamen Organics Limited. has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Delhi Ii.
Charges
A charge with Axis Bank Limited of Rs. 8.50 Cr registered on 27 Nov 2019 with Charge ID 100307662 was modified on 31 Oct 2025.
AGM
Medicamen Organics Limited. last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 0.24 Cr with Charge ID 101171485 was registered on 28 Jun 2025.
Ceased
Shailesh Harimohan Gaur ceased to be Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.16 Cr with Charge ID 100941572 was registered on 26 Jun 2024.
Charges
A charge with Axis Bank Limited amounted to Rs. 0.17 Cr with Charge ID 100888249 was registered on 15 Mar 2024.
Appointed
Varsha Bansal was appointed as Company Secretary.
Appointed
Rakesh Kumar was appointed as Director.
Appointed
Rajinder Kumar Gupta was appointed as Director.
Appointed
Sachin Gupta was appointed as Director.
29 earlier events are in the company report.
News
Frequently asked questions
Medicamen Organics Limited is an active public limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 15 March 1995 (31+ years old) and is registered under CIN L74899DL1995PLC066416. Listed on NSE: MEDIORG.
Medicamen Organics Limited reported revenue of ₹22.63 Cr for FY 2025-26 (down 40.7% YoY) based on consolidated financials.
Medicamen Organics Limited has 7 current directors:
- Bal Kishan Gupta - Managing Director
- Ashutosh Gupta - Whole-Time Director
- Rakesh Kumar - Director
- Rajinder Kumar Gupta - Director
- Sneh Gaur - Director
- Sachin Gupta - Director
- Pankaj Tiwari - Director
The latest financial statements of Medicamen Organics Limited on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Medicamen Organics Limited is 07AABCM4302P1ZF, registered in Delhi. The company has 5 GST registrations in all, of which 4 are active and 1 is cancelled or inactive. Other active GSTINs include 05AABCM4302P1ZJ (Uttarakhand), 05AABCM4302P2ZI (Uttarakhand), 05AABCM4302P3ZH (Uttarakhand).
The CIN (Corporate Identification Number) of Medicamen Organics Limited is L74899DL1995PLC066416. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Medicamen Organics Limited is a listed company as per MCA records. Its shares are listed on NSE (symbol: MEDIORG).
Medicamen Organics Limited has 26 court cases on record: 9 filed by the company and 17 filed against it. 7 are pending. Most are in the district courts.
Medicamen Organics Limited was incorporated on 15 March 1995, making it 31+ years old. It is registered with the Registrar of Companies, Delhi.
Medicamen Organics Limited has 1 deal on record (1 ipo); the latest was in June 2024.
The peers of Medicamen Organics Limited by revenue are Sigma Laboratories Private Limited, Revinto Life Science Private Limited, Ultra Laboratories Private Limited, Diamond Drugs Private Limited, Klar Sehen Pvt Ltd and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Pankaj Tiwari was appointed as Director on 09 Apr 2026. Shailesh Harimohan Gaur ceased to be Director on 20 Oct 2024. Varsha Bansal was appointed as Company Secretary on 04 Jan 2024. Medicamen Organics Limited has 22 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages